Physician
SMSJ Tucson Holdings LLC
SMSJ Tucson Holdings LLC was paid $29.82M by Medicaid between Jan 2018 and Dec 2024, across 310 billing codes. Its largest line is 99283, emergency room visit (moderate) — 23% of everything it billed.
33Billing provider infoSMSJ TUCSON HOLDINGS LLC
TUCSON, AZ 85745
TUCSON, AZ 85745
33aNPI1265818488assigned 08/11/2015
33bProvider typeDiagnostic Radiology Physician
28Total paid$29.82M
24GClaims933,393
24DCodes billed310
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Diagnostic Radiology Physician providers in Arizona
Rank by total paid#2 of 132
Median peer was paid$6K
This provider vs. median4,613×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 229,550 | $6.62M | |
| 2019 | 196,084 | $6.12M | |
| 2020 | 119,354 | $3.67M | |
| 2021 | 115,345 | $3.61M | |
| 2022 | 109,075 | $3.69M | |
| 2023 | 89,835 | $3.31M | |
| 2024incomplete | 74,150 | $2.80M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 23% | 46,224 | 41,568 | $6.95M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 22% | 39,358 | 34,915 | $6.63M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 8.9% | 5,800 | 5,318 | $2.65M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.5% | 12,474 | 11,344 | $1.63M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 5.3% | 4,351 | 4,002 | $1.59M |
| 70450 | Computed tomography, head or brain; without contrast material | 5.1% | 8,564 | 7,762 | $1.51M |
| 72125 | Computed tomography, cervical spine; without contrast material | 2.7% | 2,536 | 2,349 | $799K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 2.3% | 4,953 | 1,970 | $691K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 2.3% | 816 | 695 | $680K |
| G0378 | Hospital observation service, per hour | 2.1% | 9,800 | 5,237 | $625K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.9% | 6,569 | 6,061 | $564K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.8% | 1,581 | 1,429 | $538K |
298 more codes
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.6% | 941 | $484K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.5% | 16,749 | $438K |
| 47563 | 1.2% | 110 | $367K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.1% | 6,478 | $320K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 3,420 | $175K |
| 93458 | <1% | 111 | $172K | |
| 97602 | <1% | 2,217 | $170K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,712 | $157K |
| 49083 | <1% | 443 | $151K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 148 | $149K |
| 72131 | <1% | 983 | $146K | |
| 10060 | <1% | 815 | $140K | |
| 70486 | <1% | 587 | $133K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,619 | $129K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 1,601 | $114K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 9,338 | $102K |
| 73564 | <1% | 2,716 | $96K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 199 | $92K |
| 97113 | <1% | 1,441 | $88K | |
| C1781 | Mesh (implantable) | <1% | 352 | $88K |
| 12001 | <1% | 507 | $86K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,680 | $81K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 956 | $77K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,559 | $70K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 467 | $64K |
| 73030 | <1% | 1,995 | $63K | |
| 87070 | <1% | 4,914 | $46K | |
| 29581 | <1% | 4,086 | $46K | |
| 29125 | <1% | 301 | $45K | |
| 97162 | <1% | 1,044 | $45K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 9,787 | $41K |
| 70498 | <1% | 100 | $33K | |
| 88304 | <1% | 2,723 | $30K | |
| 93798 | <1% | 532 | $25K | |
| 93971 | <1% | 1,702 | $25K | |
| 71250 | <1% | 268 | $24K | |
| 12002 | <1% | 134 | $24K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,056 | $22K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 26,002 | $22K |
| 97163 | <1% | 292 | $21K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 446 | $16K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 660 | $16K |
| 71045 | Radiologic examination, chest; single view | <1% | 15,486 | $16K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,721 | $15K |
| 80053 | Comprehensive metabolic panel | <1% | 54,249 | $14K |
| 97750 | <1% | 595 | $14K | |
| 88341 | <1% | 36 | $13K | |
| 84484 | <1% | 20,317 | $12K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 16,426 | $12K |
| 29515 | <1% | 104 | $11K | |
| 73130 | <1% | 2,078 | $11K | |
| 73630 | <1% | 2,180 | $9K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 10,345 | $9K |
| 97116 | <1% | 1,232 | $9K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 952 | $9K |
| 90935 | Hemodialysis procedure with single evaluation by a physician | <1% | 84 | $8K |
| 73110 | <1% | 924 | $8K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 27 | $8K |
| 72110 | <1% | 187 | $7K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 31 | $7K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 38 | $7K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 7,481 | $7K |
| 97597 | <1% | 488 | $6K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,555 | $5K |
| 76770 | <1% | 214 | $5K | |
| 73610 | <1% | 1,766 | $5K | |
| 97161 | <1% | 201 | $4K | |
| 88307 | <1% | 191 | $4K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 19,746 | $4K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 19 | $4K |
| 77080 | <1% | 174 | $4K | |
| 10061 | <1% | 14 | $3K | |
| 80320 | <1% | 2,651 | $3K | |
| 73502 | <1% | 876 | $3K | |
| 72100 | <1% | 825 | $3K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 57,880 | $3K |
| 93970 | <1% | 138 | $3K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,430 | $3K |
| 11045 | <1% | 57 | $3K | |
| 72128 | <1% | 40 | $3K | |
| 74018 | <1% | 332 | $2K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 781 | $2K |
| 12011 | <1% | 12 | $2K | |
| 29130 | <1% | 12 | $2K | |
| 76830 | Ultrasound, transvaginal | <1% | 461 | $2K |
| 97166 | <1% | 206 | $2K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 11,891 | $2K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 11,073 | $2K |
| 82803 | <1% | 307 | $2K | |
| 77065 | Tomosynthesis, mammo | <1% | 31 | $2K |
| 72070 | <1% | 207 | $2K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 5,536 | $2K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 17 | $2K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 248 | $2K |
| 72050 | <1% | 41 | $2K | |
| 81001 | <1% | 24,736 | $1K | |
| 83880 | <1% | 4,595 | $1K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 837 | $1K |
| 73080 | <1% | 232 | $1K | |
| 36410 | <1% | 32 | $1K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 10,641 | $1K |
| 80143 | <1% | 780 | $1K | |
| 71101 | <1% | 232 | $1K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 5,037 | $952.67 |
| 72040 | <1% | 189 | $888.46 | |
| 87040 | <1% | 3,485 | $883.17 | |
| 73560 | <1% | 29 | $849.71 | |
| 73140 | <1% | 178 | $780.31 | |
| 83735 | <1% | 25,574 | $766.61 | |
| 83690 | <1% | 15,607 | $731.54 | |
| 81025 | <1% | 11,647 | $704.83 | |
| 73590 | <1% | 409 | $685.91 | |
| 80061 | Lipid panel | <1% | 946 | $656.57 |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 12 | $643.58 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 207 | $577.46 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 4,049 | $563.05 |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 162 | $559.69 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 3,277 | $557.05 |
| 85027 | <1% | 6,111 | $524.61 | |
| 85610 | <1% | 8,842 | $512.01 | |
| 85730 | <1% | 4,441 | $506.72 | |
| 96367 | <1% | 744 | $495.80 | |
| 87186 | <1% | 3,699 | $474.62 | |
| 93017 | <1% | 819 | $438.19 | |
| 97014 | <1% | 668 | $429.09 | |
| 84702 | <1% | 2,212 | $420.42 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,741 | $399.90 |
| 76642 | <1% | 55 | $373.69 | |
| 82948 | <1% | 18,850 | $369.43 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 22 | $360.49 |
| 87073 | <1% | 2,194 | $351.13 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 19,086 | $318.47 |
| 96376 | <1% | 6,142 | $289.05 | |
| 36592 | <1% | 374 | $280.78 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,035 | $269.61 |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 270 | $249.00 |
| 87088 | <1% | 5,574 | $247.86 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,369 | $234.85 |
| 90715 | <1% | 2,442 | $233.17 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 10,572 | $184.15 |
| 80047 | <1% | 1,771 | $179.33 | |
| A9270 | Non-covered item or service | <1% | 41,361 | $177.35 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 11,680 | $176.90 |
| 87430 | <1% | 2,268 | $171.02 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 10,515 | $156.26 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,516 | $153.51 |
| 87634 | <1% | 758 | $150.85 | |
| 83605 | <1% | 4,488 | $148.88 | |
| 84703 | <1% | 1,965 | $135.61 | |
| 85379 | <1% | 2,574 | $123.38 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 319 | $116.97 |
| 74019 | <1% | 127 | $116.61 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 3,533 | $101.50 |
| 87147 | <1% | 1,464 | $96.84 | |
| 74022 | <1% | 25 | $96.25 | |
| 76857 | <1% | 27 | $92.98 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 91 | $90.30 |
| G0379 | Direct admission of patient for hospital observation care | <1% | 13 | $84.54 |
| 86850 | <1% | 1,364 | $67.55 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,876 | $64.25 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 5,750 | $63.07 |
| 84132 | <1% | 1,381 | $60.76 | |
| 87077 | <1% | 3,017 | $58.76 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,171 | $56.39 |
| 81003 | <1% | 3,038 | $55.85 | |
| 82550 | <1% | 1,874 | $53.82 | |
| 73090 | <1% | 169 | $50.85 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,213 | $48.59 |
| 99152 | <1% | 1,007 | $47.50 | |
| 82565 | <1% | 1,765 | $46.70 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 6,877 | $43.35 |
| 82947 | <1% | 900 | $43.15 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 5,655 | $38.48 |
| 86901 | <1% | 1,874 | $38.15 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,213 | $30.49 |
| 86900 | <1% | 1,878 | $25.58 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 892 | $24.22 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 4,092 | $23.94 |
| 80076 | <1% | 153 | $22.39 | |
| 85651 | <1% | 1,258 | $21.95 | |
| 85014 | <1% | 2,785 | $21.61 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 659 | $21.60 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,681 | $20.56 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,178 | $19.18 |
| 87205 | <1% | 3,024 | $19.11 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,019 | $16.16 |
| 94664 | <1% | 419 | $15.32 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,782 | $14.40 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,495 | $13.38 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 7,628 | $12.99 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,317 | $11.19 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 770 | $9.90 |
| 87807 | <1% | 285 | $8.57 | |
| 82272 | <1% | 551 | $6.59 | |
| J3490 | Unclassified drugs | <1% | 158 | $5.99 |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 34 | $4.32 |
| J1815 | Injection, insulin, per 5 units | <1% | 506 | $2.76 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 1,277 | $1.16 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 1,472 | $0.00 |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 144 | $0.00 |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | 0% | 183 | $0.00 |
| 87210 | 0% | 607 | $0.00 | |
| 82010 | 0% | 434 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 1,509 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 35 | $0.00 |
| 84100 | 0% | 1,194 | $0.00 | |
| J1245 | Injection, dipyridamole, per 10 mg | 0% | 263 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 1,437 | $0.00 |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 606 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 583 | $0.00 |
| 82248 | 0% | 186 | $0.00 | |
| A6196 | Alginate or other fiber gelling dressing, wound cover, sterile, pad size 16 sq. in. or less, each dressing | 0% | 164 | $0.00 |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 0% | 203 | $0.00 |
| G8989 | Self care functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 152 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 644 | $0.00 |
| C1729 | Catheter, drainage | 0% | 537 | $0.00 |
| 82140 | 0% | 208 | $0.00 | |
| A6021 | Collagen dressing, sterile, size 16 sq. in. or less, each | 0% | 132 | $0.00 |
| 84520 | 0% | 73 | $0.00 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 235 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 564 | $0.00 |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 33 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 132 | $0.00 |
| 74300 | 0% | 110 | $0.00 | |
| 87045 | 0% | 14 | $0.00 | |
| 84295 | 0% | 50 | $0.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 55 | $0.00 |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | 0% | 40 | $0.00 |
| 85347 | 0% | 20 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 78 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 17 | $0.00 |
| Q2038 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone) | 0% | 79 | $0.00 |
| 36600 | 0% | 23 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 25 | $0.00 |
| C1758 | Catheter, ureteral | 0% | 45 | $0.00 |
| 89051 | 0% | 31 | $0.00 | |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | 0% | 15 | $0.00 |
| 97167 | 0% | 15 | $0.00 | |
| 87899 | 0% | 18 | $0.00 | |
| 87324 | 0% | 14 | $0.00 | |
| J0153 | Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 0% | 37 | $0.00 |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | 0% | 14 | $0.00 |
| 82374 | 0% | 13 | $0.00 | |
| C1769 | Guide wire | 0% | 1,810 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 273 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 192 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 131 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 1,072 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 241 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 1,795 | $0.00 |
| 82330 | 0% | 16 | $0.00 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 329 | $0.00 |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 61 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 42 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 374 | $0.00 |
| 88342 | 0% | 1,653 | $0.00 | |
| J7999 | Compounded drug, not otherwise classified | 0% | 645 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 196 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 2,357 | $0.00 |
| 94760 | 0% | 1,718 | $0.00 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 334 | $0.00 |
| 77001 | 0% | 13 | $0.00 | |
| A6207 | Contact layer, sterile, more than 16 sq. in. but less than or equal to 48 sq. in., each dressing | 0% | 503 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 1,633 | $0.00 |
| J1805 | Injection, esmolol hydrochloride, 10 mg | 0% | 26 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 725 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 228 | $0.00 |
| 80051 | 0% | 72 | $0.00 | |
| 87490 | 0% | 131 | $0.00 | |
| 76801 | 0% | 304 | $0.00 | |
| 36416 | 0% | 3,084 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 205 | $0.00 |
| 88311 | 0% | 454 | $0.00 | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 56 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 176 | $0.00 |
| J0456 | Injection, azithromycin, 500 mg | 0% | 82 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 120 | $0.00 |
| 87015 | 0% | 236 | $0.00 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 62 | $0.00 |
| 95886 | 0% | 12 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 0% | 36 | $0.00 |
| 70496 | 0% | 80 | $0.00 | |
| 82435 | 0% | 50 | $0.00 | |
| 85018 | 0% | 17 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 176 | $0.00 |
| J0280 | Injection, aminophyllin, up to 250 mg | 0% | 74 | $0.00 |
| 90732 | 0% | 13 | $0.00 | |
| 86140 | 0% | 82 | $0.00 | |
| 99406 | 0% | 51 | $0.00 | |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 23 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 97 | $0.00 |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 0% | 27 | $0.00 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 0% | 23 | $0.00 |
| 73060 | 0% | 15 | $0.00 | |
| 76870 | 0% | 12 | $0.00 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 20 | $0.00 |
| 88300 | 0% | 15 | $0.00 | |
| 82150 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCORMIER, CRISTIAN (CFO)
| Provider | Location | Paid |
|---|---|---|
| SMSJ Tucson Holdings LLC | Tucson, AZ | $28.93M |
| SMSJ Tucson Holdings, LLC | Tucson, AZ | $2.95M |
| SMSJ Tucson Holdings LLC | Tucson, AZ | $2.43M |
| SMSJ Tucson Holdings, LLC | Tucson, AZ | $25K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.